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Abstract
The overall malaria burden in the Americas has decreased dramatically over the past two
decades, but residual transmission pockets persist across the Amazon Basin, where Plas-
modium vivax is the predominant infecting species. Current elimination efforts require a bet-
ter quantitative understanding of malaria transmission dynamics for planning, monitoring,
and evaluating interventions at the community level. This can be achieved with mathemati-
cal models that properly account for risk heterogeneity in communities approaching elimina-
tion, where few individuals disproportionately contribute to overall malaria prevalence,
morbidity, and onwards transmission. Here we analyse demographic information combined
with routinely collected malaria morbidity data from the town of Maˆncio Lima, the main urban
transmission hotspot of Brazil. We estimate the proportion of high-risk subjects in the host
population by fitting compartmental susceptible-infected-susceptible (SIS) transmission
models simultaneously to age-stratified vivax malaria incidence densities and the frequency
distribution of P. vivax malaria attacks experienced by each individual over 12 months. Sim-
ulations with the best-fitting SIS model indicate that 20% of the hosts contribute 86% of the
overall vivax malaria burden. Despite the low overall force of infection typically found in the
Amazon, about one order of magnitude lower than that in rural Africa, high-risk individuals
gradually develop clinical immunity following repeated infections and eventually constitute a
substantial infectious reservoir comprised of asymptomatic parasite carriers that is over-
looked by routine surveillance but likely fuels onwards malaria transmission. High-risk indi-
viduals therefore represent a priority target for more intensive and effective interventions
that may not be readily delivered to the entire community.
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Author summary
Malaria transmission models that disregard risk heterogeneity at the community level,
classifying individuals as uniformly susceptible or infected, may not properly recapitulate
the epidemiology of malaria in real-life settings. Here we fit a compartmental susceptible-
infected-susceptible model to malaria morbidity data from Maˆncio Lima, the main urban
transmission hotspot of Brazil, and estimate that 20% of the urban residents contribute
86% of the overall vivax malaria burden in the town. Despite the low average force of
infection, one order of magnitude lower that in rural Africa, high-risk individuals experi-
ence enough repeated infections to develop clinical immunity and constitute an asymp-
tomatic reservoir that fuels onwards malaria transmission. Therefore, these high-risk
subjects account for the paradoxical finding of clinical immunity and frequent asymptom-
atic parasite carriage in low-endemicity Amazonian communities. We argue that mathe-
matical models accounting for risk heterogeneity are crucial to plan and evaluate malaria
control and elimination interventions targeted to high-risk groups in communities,
municipalities, and regions.
Introduction
Heterogeneity in the risk of infection with several pathogens has been repeatedly documented
in human populations, with 20% of the hosts typically harbouring 80% of the pathogen burden
in the community [1]. For example, residents in the same village in rural Africa may greatly
differ in their malaria risk, leading to over-dispersed frequency distributions of malaria attacks
per person over time, with few subjects in the community experiencing frequent infection and
disease [2].
One source of malaria risk heterogeneity is the varying hosts’ exposure to the pathogen,
which can be measured as the number of infectious mosquito bites per host per unit of time,
termed the entomological inoculation rate (EIR). About 20% of the children are estimated to
receive 80% of all infectious mosquito bites in rural African settings, suggesting that malaria
parasites may also conform to the “20/80 rule” [3]. Significant malaria risk heterogeneity has
also been described in towns and cities in Africa [4–6]. For example, EIRs across the city of
Brazzaville were estimated in the early 1980s to range between <1 every three years and >100
per year [7]. Not surprisingly, community-wide EIR measurements are affected by a range of
environmental factors (e.g., proximity of houses to water bodies that serve as larval habitats for
vectors), behavioural characteristics of individuals (e.g., occupational exposure to mosquitoes
and patterns of bednet use), and individual differences in attractiveness to mosquitoes [e.g., 8].
Variation in overall malaria risk may also result from differences in individual susceptibility to
infection and subsequent disease given exposure, due to innate resistance and acquired immu-
nity developing after repeated infections [9].
A quantitative understanding of malaria transmission dynamics is required for planning,
monitoring, and evaluating interventions aimed at its elimination [10]. However, classical sus-
ceptible-infected-susceptible (SIS) malaria models often disregard, totally or partially, risk het-
erogeneity at the community level and classify hosts as more uniformly susceptible or
infectious than they actually are. Models that take insufficient account of real-world heteroge-
neities may not properly recapitulate the transmission dynamics of malaria in endemic set-
tings, in addition to not providing insights into the impact of targeting control interventions
to high-risk groups [1, 10]. SIS models of infectious diseases may incorporate risk heterogene-
ity among hosts as, for example, a continuous distribution of hosts’ susceptibility to infection,
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which can be determined empirically from the proportions of hosts that are experimentally
infected at different pathogen challenge doses [11–13]. Alternatively, models may assume that
the population of susceptible individuals is divided into a finite number of susceptibility classes
or frailty groups [13–17].
The incidence of malaria in the Americas has decreased dramatically over the past two
decades, but residual transmission pockets persist across the Amazon and challenge current
elimination efforts. Residual malaria refers to the transmission that persists despite achieving
high coverage of effective control measures such as use of insecticide-treated bednets and
indoor residual spraying [18]. Plasmodium vivax, the predominant human malaria parasite in
the region, is found in nearly 76% of cases in this continent [19]. Here, we fit compartmental
SIS models that incorporate risk heterogeneity to malaria surveillance data, aiming to explore
the transmission dynamics of P. vivax in the main urban malaria hotspot of the Amazon Basin
of Brazil.
Results
A homogeneous-risk model does not satisfactorily recapitulate the
epidemiology of Plasmodium vivax malaria
We first fitted empirical data by using a compartmental SIS model that considers the entire
host population as being homogeneously at risk (p1 = 1 and x1 = 1; parameters are described in
Materials and Methods section) of clinical vivax malaria (Fig 1C). The simultaneous fitting to
empirical profiles of incidence by age and number of annual episodes per person (parameter
estimation process is fully described in S1 File) is optimal when the age-dependent force of
infection (Eq 1) takes parameter values λ0 = 0.7452, c = 0.8787 and k = 0.0282 (Fig 1D) and the
partial immunity factor (Eq 2) decays at constant rate α = 0.1162 per infection experienced
(Fig 1E). The homogeneous-risk model output recapitulates how malaria incidence density
varies with age (Fig 1A; see also [20]) but does not satisfactorily fit the number of episodes per
person over the one-year follow-up (Fig 1B).
A 20% fraction of high-risk individuals accounts for 86% of the
community-wide malaria burden
We next consider two susceptibility classes (high-risk [HR] and low-risk [LR] groups) to
account for risk heterogeneity in the host population. We optimised model fitting (S1 File) for
different proportions of individuals in the HR and LR groups, with the best fit corresponding
to a model with 20% of the host population allocated to the HR group (Table 1).
The best-fitting solution obtained with the heterogeneous model is presented in Fig 2. Fig
2A compares empirical age-specific malaria incidence data to the model output, which com-
bines incidence densities in the LR and HR groups. Overall, the HR group is estimated to con-
tribute 86.0% of the overall vivax malaria burden in the community, roughly as expected from
the “20/80 rule” [1]. High-risk individuals become infected earlier and acquire partial immu-
nity faster than their low-risk counterparts, resulting in markedly different, subgroup-specific
age-incidence patterns. In the HR group, the incidence of clinical malaria sharply increases
with age among children and adolescents, but declines thereafter; in contrast, malaria inci-
dence density increases slowly in the LR group and reaches a plateau in the fourth decade of
life. Fig 2B shows that the model properly fits the empirical frequency distribution of cases per
person accumulated over one year of follow-up.
Fig 2C, 2D and 2E show, respectively, the risk distribution, the age-dependent force of
infection and the partial immunity factor. The risk distribution has variance v = 3.3247 [95%
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credible interval: 3.1057–3.3845], with 80% (p1 = 0.8) of the population having low risk x1 =
0.0883 [95% CI: 0.0801–0.1189]) (LR group) and 20% (p2 = 0.2) high risk x2 = 4.6467 [95% CI:
4.5246–4.6794]) (HR group). Note that P. vivax malaria risk is approximately 26-fold higher in
individuals in the S0,2 compartment, which comprises malaria-naïve high-risk subjects, com-
pared to their counterparts in the S0,1 compartment, which comprises malaria-naïve low-risk
subjects. However, this difference changes with age as individuals in each group become
infected and acquire partial immunity. The model fits the data optimally when the age-depen-
dent force of infection (Eq 1) takes parameter values λ0 = 0.6197 [95% CI: 0.3680–0.7174],
Fig 1. Model with homogeneous risk. (A) Age-specific malaria incidence data (red circles) and the best fitting model output (blue line). (B)
Frequency distribution of the number of cases per person, empirical data (red bars) and model output (blue bars). (C) Homogeneous risk
distribution. (D) Age-dependent force of infection (Eq 1) with parameters λ0 = 0.7452, c = 0.8787 and k = 0.0282. (E) Partial immunity factor (Eq 2)
with parameter α = 0.1162.
https://doi.org/10.1371/journal.pcbi.1007377.g001
Table 1. Model fitting for different risk distributions.
HR-LR (in %) Log-likelihood
0–100 118.4802
10–90 133.2681
15–85 141.4236
20–80 142.6645
25–75 140.6231
30–70 137.4449
https://doi.org/10.1371/journal.pcbi.1007377.t001
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c = 0.8720 [95% CI: 0.6638–0.9642] and k = 0.0493 [95% CI: 0.0392–0.1173], and the partial
immunity factor (Eq 2) decays at rate α = 0.0285 per infection [95% CI: 0.0162–0.0330].
High-risk individuals develop immunity and constitute a clinically silent
reservoir of infection
We next incorporate to the model, compartments with individuals who are infected but
asymptomatic. The dynamics of individuals through model compartments, considering that
asymptomatic infections last an average of 90 days (i.e. γ0 = 1/90 per day), is shown in Fig 3.
Individuals in the LR group move slowly between compartments (Fig 3A, 3B and 3C), com-
pared with their HR counterparts (Fig 3D, 3E and 3F). Using the population age structure
determined by our census survey, the model predicts that, in the current population, 77.8%
and 5.4% of the individuals of the HR and LR groups, respectively, had at least one clinical
malaria attack. As a consequence, acquired immunity following repeated P. vivax malaria epi-
sodes affects almost exclusively the dynamics of HR individuals, leading to frequent asymp-
tomatic infections (Fig 3C and 3F).
Fig 2. Model with heterogeneous risk. (A) Age-stratified incidence data (red circles) and the model output (blue line) as a composition of incidence
densities in the low-risk (LR; red line) and high-risk (HR; yellow) groups. (B) Frequency distribution of the number of cases per person, empirical
data (red bars) and model output (blue bars). (C) Risk distribution with variance v = 3.3247 [95% credible interval: 3.1057–3.3845], partitioning the
population into 80% (p1 = 0.8) in the LR group (x1 = 0.0883 [95% CI: 0.0801–0.1189]) and 20% (p2 = 0.2) in the HR group (x2 = 4.6467 [95% CI:
4.5246–4.6794]). (D) Age-dependent force of infection (Eq 1) with parameters λ0 = 0.6197 [95% CI: 0.3680–0.7174], c = 0.8720 [95% CI: 0.6638–
0.9642] and k = 0.0493 [95% CI: 0.0392–0.1173]. (E) Partial immunity factor (Eq 2) with parameter α = 0.0285 [95% CI: 0.0162–0.0330].
https://doi.org/10.1371/journal.pcbi.1007377.g002
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Because the asymptomatic infection recovery rate γ0 is unknown, we assumed the average
duration of asymptomatic parasite carriage (DA) to range from 30 to 180 days (Fig 4). Model
outputs recapitulate the age-dependent increase in the prevalence of asymptomatic P. vivax
carriage that has been described in Amazonian communities (Fig 4A; e.g., [21]) and, as
expected, indicate that the community-wide prevalence of asymptomatic P. vivax infection
increases with longer parasite carriage duration (Fig 4B). Model simulations indicate that HR
individuals constitute the vast majority of asymptomatic parasite carriers (Fig 4C). Although
this maybe somewhat overrated due to the assumption that acquired immunity reduces symp-
toms without preventing infection, it highlights plausible trends warranting future empirical
studies.
The relative contribution of asymptomatic and symptomatic infections to the overall bur-
den of P. vivax infection in the community was also simulated (Fig 5). We observe that, even
with short-lived asymptomatic parasite carriage (DA = 1/γ0 = 30 days) and considering the
average duration of symptomatic infections that are diagnosed and treated as either 4, 8, or 12
days, 66–85% of subjects carrying P. vivax infection at a given time will be asymptomatic, con-
sistent with empirical estimates from across the Amazon ranging between 52% and 90% [21–
24]. We note that these empirical data can be used to estimate γ0 and DA in the target
populations.
Finally, we simulated the relative contribution of asymptomatic parasite carriers to onwards
P. vivax transmission in a wide range of plausible scenarios. To this end, we consider that
symptomatic and asymptomatic parasite carriers remain infectious for 4, 8 and 12 days and
30, 90 and 180 days, respectively, with a relative infectiousness (RI) of asymptomatic compared
to symptomatic infections of 1/2, 1/10 and 1/30 (Fig 6). Model outputs indicate that even
Fig 3. Age-profiles of repeated malaria in a heterogeneous host population comprising a high-risk (HR) and a low-risk (LR) group. (A) Susceptible individuals in
the LR group; (B) Symptomatic infected individuals in the LR group; (C) Asymptomatic individuals in the LR group; (D) Susceptible individuals in the HR group; (E)
Symptomatic infected individuals in the HR group; (F) Asymptomatic individuals in the HR group.
https://doi.org/10.1371/journal.pcbi.1007377.g003
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short-lived asymptomatic P. vivax carriage (DA = 30 days) can contribute substantially to
onwards malaria transmission in the community if the overall RI ranges between 1/2 and 1/10
(Fig 6A and 6D). Sustained asymptomatic P. vivax carriage (DA = 90 days) can account for 30–
87% of the infectious reservoir if RI ranges between 1/2 and 1/10 (Fig 6B and 6E), with a
minor further increase with DA = 180 days (Fig 6C and 6F). We further note that, for most DA
and RI value combinations, the relative contribution of symptomatic infections to the infec-
tious reservoir can be substantially reduced by providing prompt CQ-PQ treatment to reduce
the mean gametocyte clearance time (or average duration of infectiousness) from 12 to 4 days.
Fig 4. Prevalence of asymptomatic Plasmodium vivax infection according to the average duration of parasite carriage. (A) Age-stratified prevalence of
asymptomatic infection considering an average duration of asymptomatic parasite carriage DA of 30, 90 and 180 days. (B) Variation in the community-wide
prevalence of asymptomatic infection according to the average duration of asymptomatic parasite carriage. (C) Age-stratified prevalence of asymptomatic
infection in the low-risk (LR) and high-risk (HR) groups considering an average duration of asymptomatic parasite carriage DA of 30 days (upper panel), 90
days (middle panel) or 180 days (lower panel).
https://doi.org/10.1371/journal.pcbi.1007377.g004
Fig 5. Simulated proportions of community-wide Plasmodium vivax infections that are symptomatic or asymptomatic. We consider the average duration of
symptomatic infections that are diagnosed and treated as either 4, 8, or 12 days; the duration of asymptomatic parasite carriage that remains undetected and
untreated (DA) is considered to be 30 days (panel A), 90 days (panel B), or 180 days (panel C).
https://doi.org/10.1371/journal.pcbi.1007377.g005
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Discussion
Measuring how malaria infection risk varies among individuals is challenging. Product of
exposure to infectious mosquitoes and susceptibility to infection given exposure, each individ-
ual’s risk is determined by numerous interacting factors. Despites notorious efforts being
invested in characterising specific determinants, such as individual mobility to and from hot-
spots [25], parasite genetics [26] and human genetics [27], a complete catalogue of risk factors
and respective measures is not on the horizon. Smith [28] suggested that individual-level varia-
tion in susceptibility to malaria given exposure can be inferred by modelling malaria incidence
as a function of EIR measured in the same population. Similarly, matched EIR and parasite
prevalence data have been used to quantify heterogeneity in malaria susceptibility by assuming
a gamma distribution of relative infection rates in the host population [5]. However, the wide-
spread use of these approaches is limited by the restricted availability of reliable EIR measure-
ments, which are notoriously difficult to obtain, from across endemic communities. Malaria
transmission models that consider heterogeneity have instead assumed either a small number
of measured risk factors or unmeasured ranges of individual risk variation incorporated as
either discrete frailty groups or a continuous variable (e.g., [29]).
Here, we show that a compartmental SIS model with heterogeneous risk notoriously out-
performs its mean-field approximation in recapitulating the transmission dynamics of P. vivax
in the main malaria hotspot of Brazil. We provide an empirical basis to estimate risk
Fig 6. Relative contribution to the Plasmodium vivax infectious reservoir of individuals with symptomatic and asymptomatic infections. Model outputs
consider different average durations of asymptomatic parasite carriage DA (DA = 30 days in panels A, D and G; 90 days in panels B, E and H; and 180 days in
panels C, F and I) and different relative infectiousness (RI) of asymptomatic compared to symptomatic infections (RI = 1/2 in panels A, B and C; 1/10 in panels D,
E and F; and 1/30 in panels G, H and I. For every combination of DA and RI, we simulated the average duration of infectiousness of symptomatic infections as
either 4, 8 or 12 days.
https://doi.org/10.1371/journal.pcbi.1007377.g006
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heterogeneity in host populations by simultaneously fitting SIS models to two sets of surveil-
lance data—namely, age-related malaria incidence and frequency distribution of malaria cases
per person—derived from the same population-based cohort. The best-fitting heterogeneous-
risk model considers that the HR group comprises 20% of the host population and contributes
86% of the vivax malaria burden in the community. We suggest that this approach can be used
to fit empirical data from across a range of malaria-endemic settings to test whether other host
populations conform to this 20/80 pattern.
The estimated force of infection in the main residual malaria hotspot of Brazil is one order
of magnitude lower than that estimated for P. falciparum in children from across rural Africa
(e.g., [20, 30]). As a consequence, our study population appears to acquire partial immunity to
malaria rather slowly. Indeed, the model predicts that as much as 25 past clinical malaria
attacks, on average, are required in order to reduce by half the risk of a clinical malaria attack.
In holoendemic settings, children are typically continuously infected during the transmission
season, with frequent superinfection and overlapping clinical malaria episodes during their
first years of life. For example, children aged 1–5 years in Papua New Guinea were estimated
to experience an average of 2.5 episodes of clinical vivax malaria per year in 2006–2007, before
intensified, large-scale control interventions were implemented nationwide [31]. Similarly, in
Mali an average of 2.4 episodes of clinical falciparum malaria per child aged 3–59 months per
year have been estimated to occur, despite the distribution of long-lasting insecticide-treat bed
nets at baseline [32]. Both estimates give an average of 25 malaria attacks by the age of 10–11
years. Indeed, in such areas, malaria remains common throughout most of childhood, and a
significant decrease in risk of infection is seen in adolescence and early adulthood. In our
study site, although partial immunity develops earlier in the HR group, with a decline in
malaria incidence after the second decade of life (Fig 2A), HR individuals across all age groups
still constitute the main contributors to the overall clinical malaria burden.
Despite the low overall force of infection in the study area, the fraction of HR individuals
who experience repeated P. vivax infections and gradually develop partial immunity will eventu-
ally become asymptomatic but potentially infectious parasite carriers overlooked by routine sur-
veillance. Although the overall average incidence of clinical P. vivax malaria in Maˆncio Lima,
estimated at 20.90 episodes/100 person-years at risk between October 2015 and September 2016,
is substantially lower than that observed in holoendemic settings, some HR individuals may be
nearly as exposed to malaria as the average child living in rural Africa. In fact, around one fourth
of study subjects experienced one or more episodes of clinical vivax malaria during the study
period; 29.9% of those with symptomatic P. vivax infections diagnosed during the study period
had two or more episodes (Fig 2B, red bars), indicating that a fraction of exposed subjects actually
experience repeated P. vivax episodes over one year of follow-up. Therefore, the paradoxical find-
ing of clinical immunity and frequent asymptomatic infections in Amazonian communities
exposed to low overall levels of malaria transmission [33] can be explained by the presence of a
fraction of HR subjects that experience the majority of infections in the community and acquire
clinical immunity. Statistical modelling of malaria surveillance data has identified young adult
males living in the less urbanized periphery of the town as the main HR individuals in Maˆncio
Lima [34]. Importantly, these HR individuals not only contribute disproportionately to the overall
burden of clinical disease (Fig 2A), but also constitute the silent reservoir of sustained asymptom-
atic infections (Fig 4C) that are left untreated and may contribute significantly to onwards malaria
transmission in this and other low-endemicity settings [35]. Estimates of the proportions of
asymptomatic infections that are patent (consistent with RI close to 1/2) vary by one order of mag-
nitude, from 4.5% [24] to 46.7% [22], in Amazonian populations.
The importance of characterising malaria reservoirs in endemic regions has recently been
highlighted [36] and the results from this work further underscore how essential this
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information is to inform elimination programmes for properly planning control interventions.
Heterogeneous risk implies that imperfect control measures, such as leaky vaccines, if uni-
formly applied to the entire host population, are unlikely to reduce substantially the overall
malaria burden [29]. Our model simulations, however, suggest that a dramatic reduction in
the community-level burden of clinical P. vivax malaria can be achieved by selectively target-
ing HR subjects, if they can be readily identified, to more intensive and effective measures that
may not be readily delivered to the entire population.
We have limited the present analysis to P. vivax, which predominates in the areas of resid-
ual malaria transmission across the Amazon Basin. One major feature of P. vivax is that para-
sites may persist for several months in human hosts as hypnozoites, the dormant liver stages
that eventually reactivate and may cause one or more new blood-stage infections termed
relapses following a single infectious mosquito bite [37]. Radical cure of vivax malaria thus
requires the use of antimalarial drugs that target both blood and liver stages, such as PQ and
tafenoquine. Although we do not consider relapses explicitly in our compartmental models,
they are implicitly integrated into the force of infection, which combines blood-stage infec-
tions arising from infecting stages (sporozoites) inoculated during mosquito bites and relapses
arising from reactivating hypnozoites. We hypothesise that HR and LR individuals initially dif-
fer in their exposure to infectious mosquitoes or susceptibility to infection and disease once
challenged with infecting sporozoites, but over time HR individuals become also more likely
to have P. vivax relapses originating from the large hypnozoite reservoir that they have accu-
mulated in the liver following repeated infections. Importantly, new infections and relapses
entail different control measures; while the incidence of new infections can be reduced by
decreasing exposure to mosquito bites, e.g. with insecticide-treated bednets, relapses can be
prevented by improved anti-relapse treatments.
The present study has some limitations. First, we used routinely collected malaria morbidity
data for model fitting, but blood samples were not available for further confirmatory (e.g.,
molecular) diagnostic tests. Moreover, surveillance data used to fit our models do not include
sub-patent and asymptomatic malaria episodes experienced by the target population. Second,
our modelling approach does not allow for estimating the impact of improved anti-relapse
therapies on the overall P. vivax malaria burden, since we do not differentiate between blood-
stage infections arising from hypnozoites and newly inoculated sporozoites. Third, there are
no empirical data, obtained in the same population, to properly measure the relative infec-
tiousness of asymptomatic infections, either patent or not, and estimate more precisely their
potential contribution to malaria transmission in the community.
We conclude that considering risk heterogeneity in the host population is crucial for prop-
erly describing the transmission dynamics of P. vivax using compartmental SIS models and
provide a framework to test the hypothesis that a few HR subjects contribute the vast majority
of the vivax malaria burden at the community level. Moreover, HR subjects are important con-
tributors to the silent infectious reservoir that likely fuels onwards malaria transmission in
low-endemicity settings. These results can be further explored for the evidence-based planning
and deployment of control interventions towards the elimination of residual P. vivax malaria
across the Amazon Basin.
Materials and methods
Ethics statement
The study protocol was approved by the Institutional Review Board of the Institute of Biomed-
ical Sciences, University of São Paulo, Brazil (CEPH-ICB 1368/17); written informed consent
and assent were obtained for the census survey.
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Study site and population
The study site, the municipality of Maˆncio Lima (07˚36’ 51"S, 72˚53’ 45"W), is situated in the
upper Jurua´ Valley, next to the border between Brazil and Peru. With 17,910 inhabitants (half
of them in the urban area) and 9,278 laboratory-confirmed malaria cases notified in 2017,
Maˆncio Lima has currently the highest annual parasite incidence (API) in Brazil, estimated at
518.0 malaria cases per 1,000 inhabitants. Maˆncio Lima is unique in Brazil in that 49% of all
local malaria infections are reportedly acquired in urban settings, compared to a country’s
average of 15% (Ministry of Health of Brazil; SIVEP-Malaria; http://portalweb04.saude.gov.br/
sivep_malaria/default.asp; accessed 04 July 2019).
The study cohort comprised 8,783 permanent residents in the town of Maˆncio Lima, aged
from <1 to 80 years and distributed into 2,329 households. These individuals were systemati-
cally enumerated during a demographic census survey carried out by our field team between
November 2015 and April 2016. Dates of entry in the study cohort were the subject0s date of
birth or October 1, 2015, whatever was the most recent; this information was used to calculate
the number of person-years at risk for incidence density estimation. For the purposes of this
analysis, we assumed that no study participant left the study area before September 30, 2016,
when the latest morbidity data were collected.
Malaria morbidity data
We retrieved all records of laboratory-confirmed clinical malaria cases notified in Maˆncio
Lima between October 1, 2015, to September 30, 2016. Case records were entered into the elec-
tronic malaria notification system of the Ministry of Health of Brazil (SIVEP-Malaria; http://
200.214.130.44/sivep_malaria/). Because malaria is a notifiable disease in Brazil and only pub-
lic health facilities provide laboratory diagnosis and malaria treatment, the electronic malaria
notification system is estimated to comprise 99.6% of all clinical malaria cases diagnosed coun-
trywide [38]. However, asymptomatic parasite carriage and persistently subpatent infections,
which are not detected by microscopy or commercially available, antigen-based rapid diagnos-
tic tests, may have been overlooked. We used patient’s name, gender, and age to link malaria
case records to individuals in our census survey database, given the absence of common
unique patient identifiers. Name entries were compared using the Jaro-Winkler string distance
[39] as implemented in the stringdist package of the R software [40]. Criteria for associating
malaria case records to subjects enumerated during our census survey were: (a) same gender,
(b) maximum reported age difference of 1 year, and (c) maximum Jaro-Winkler distance
between names of 0.10, with penalty factor of 0.05 (constant scaling factor for how much the
score is adjusted downwards for having common prefixes).
A minimal interval of 28 days between two consecutive malaria notifications was required to
count the second case as a new malaria episode. When different infecting species were detected
in samples obtained less than 28 days apart, the subject was considered to have a single mixed-
species infection. Overall, we found 2,057 malaria notifications in the cohort of urban residents
during the 12-month study period, with 8,770.8 person-years of follow-up. P. vivax accounted
for 1,833 cases (89.1%), P. falciparum for 193 cases (9.4%) and both species for 31 cases (1.5%).
The present analysis is limited to P. vivax infections, since this is the most abundant in our
study location. Describing the transmission dynamics of multiple Plasmodium species would
escalate model complexity and assumptions beyond the realm of the current study. We found
an average malaria vivax incidence density of 20.90 episodes/100 person-years at risk. By com-
bining demographic information and malaria morbidity data, we computed age-specific vivax
malaria incidence densities and the number of vivax malaria episodes per person recorded in
the urban cohort over 12 months. These empirical data were used to fit model outputs.
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The mathematical model
The compartmental SIS model describing the epidemiology of clinical vivax malaria is repre-
sented diagrammatically in Fig 7. Any population of susceptible individuals is heterogeneous
with regards to risk of infection. Individual risk is a continuous characteristic which we discre-
tise in two groups: low risk (LR) and high risk (HR). This is a coarse description of individual
heterogeneity that nevertheless suffices to our modelling purposes of capturing the effects of
variance in risk. Within each risk group, individuals are classified as either susceptible or
infected. Each risk group comprises a proportion pj (0<pj<1, j = 1,2 and p1+p2 = 1) of the total
population and is associated with a risk factor xj>0 (j = 1,2). Without loss of generality, we
assume that the overall average risk is equal to 1 (x1p1+x2p2 = 1) since the factors xj are modifi-
ers of individual responses to a force of infection which will be allowed to vary. This setting
configures a risk distribution with variance v = p1(x1−1)2+p2(x2−1)2.
We assume an age-dependent force of infection λ(a) (Eq 1), which correlates mosquito bit-
ing activity with human body mass [30, 41]. This function strictly increases with age, with min-
imum λ0(1−c) (at age zero) and upper limit λ0. The parameter k determines how steeply the
force of infection increases in early ages and c controls the value at birth.
lðaÞ ¼ l0ð1   ce
  kaÞ ð1Þ
Assuming that individuals acquire partial immunity after repeated clinical malaria attacks,
due to antibody- and cell-mediated responses [42], we introduce a factor describing the devel-
opment of partial immunity. The strictly positive decreasing function σ(i) of the number i
(i�0) of past clinical vivax malaria attacks each individual has experienced (Eq 2), with a maxi-
mum for malaria-naïve individuals (σ(0) = 1), simulates a partial immunity factor and weights
down the age-dependent force of infection λ(a) as the number of cumulative clinical malaria
episodes increases. The factor describing partial immunity is controlled by the parameter α,
which determines the rate at which immunity develops after repeated infections.
sðiÞ ¼ e  a�i ð2Þ
Assuming equilibrium with respect to time, in addition to the age-dependent force of infec-
tion, partial immunity acquisition and risk heterogeneity, malaria unfolds in age domain
according to a system of ordinary differential equations (ODEs) (system of Eq 3), with initial
Fig 7. Susceptible-infected-susceptible (SIS) compartmental model representing the dynamics of malaria over age in a
heterogeneous host population. The compartments describe the following epidemiological classes: Si,j represents susceptible
individuals from risk group j (1 = low-risk [LR]; 2 = high-risk [HR]) who have experienced i past clinical malaria attacks; Ii,j
represents symptomatic infected individuals from risk group j who are currently experiencing their ith clinical malaria attack.
Individuals experience new infections due to an age-dependent force of infection λ(a) modified by a risk factor xj, and a partial
immunity weight σ(i); all individuals recover at the same rate γ.
https://doi.org/10.1371/journal.pcbi.1007377.g007
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conditions S0,j(0) = pj, Si,j(0) = Ii,j(0) = 0, for i = 1,2,. . . and j = 1,2.
dS0;j
da
¼   xjsð0ÞlðaÞS0;j
dI1;j
da
¼ þxjsð0ÞlðaÞS0;j   gI1;j
dS1;j
da
¼   xjsð1ÞlðaÞS1;j þ gI1;j
dI2;j
da
¼ þxjsð1ÞlðaÞS1;j   gI2;j
..
.
dSn  1;j
da
¼   xjsðn  1ÞlðaÞSn  1;j þ gIn  1;j
dIn;j
da
¼ þxjsðn  1ÞlðaÞSn  1;j   gIn;j
..
.
ð3Þ
Individuals in the LR group are initially allocated to compartment S0,1, comprising suscepti-
ble individuals who are malaria-naïve. At a rate which is determined by the age-dependent
force of infection λ(a) and the risk factor x1, LR individuals move to compartment I1,1 after
experiencing their first clinical vivax malaria attack. After recovering (with recovery rate γ),
they become susceptible again and move to the next compartment S1,1, which comprises sus-
ceptible individuals who have already experienced one past malaria attack and acquired some
degree of partial immunity. These individuals may acquire a second infection, according to the
same age-dependent force of infection and risk factor, but now weighted down by the partial
immunity σ(1). LR individuals can move forward between compartments within the LR
group. With similar dynamics, HR individuals move forward within the HR group, but with a
risk factor x2 (Fig 7). This is denominated as the heterogeneous risk model.
For comparison purposes, we built a similar compartmental model where the same average
risk is applied to the entire host population (homogeneous risk model; p1 = 1 and x1 = 1, e.g.,
[20]). We fitted the heterogeneous and the homogeneous risk models to empirical data and
compared their ability to recapitulate the epidemiology of vivax malaria in the study
population.
Mathematical model with asymptomatic infections
We refined the SIS model with compartments comprising infected but asymptomatic individ-
uals, by assuming that the proportion of asymptomatic infections depends on gradually
acquired partial immunity. This partial immunity is sometimes termed “clinical” or “anti-dis-
ease immunity” to emphasise that individuals remain susceptible to infection but become
gradually less likely to develop clinical disease once infected. We followed the same basic
assumptions of the first model: susceptible individuals from risk group j, with age a and with i
past clinical attacks (Si,j(a)) develop their ith clinical case at rate xjσ(i)λ(a). Partial immunity
developed after i past attacks (Eq 2) reduces by 1−σ(i) the probability of susceptible individuals
Si,j(a) presenting clinical symptoms once infected again. Note that in this model rates of clini-
cal malaria episodes decline explicitly due to clinical immunity, in contrast with the previous
implementation which did not specify whether these declines were due to immunity against
disease or against infection. Infected subjects thus move to the asymptomatic compartment A
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if they do not develop clinical malaria upon infection. More formally, susceptible individuals
Si,j(a) become infected but asymptomatic Ai,j(a) at rate xj(1−σ(i))λ(a). Individuals with asymp-
tomatic infections from group j, age a and who experienced i past clinical malaria attacks (Ai,
j(a)) can eventually progress to their ith new clinical attack, at rate xjσ(i)λ(a), or recover and
become susceptible again at rate γ0. The compartmental SIS model considering asymptomatic
infections is represented diagrammatically in Fig 8.
We assume that naïve individuals from compartment S0,j(a) cannot remain asymptomatic
once infected for the first time, since they have not yet developed partial immunity. Indeed,
with acquired immunity modelled by an exponential function (Eq 2), we have for naïve indi-
viduals σ(0) = 1. Therefore, the probability of naïve individuals becoming infected but asymp-
tomatic is 0 (xj.0.λ(a)).
Introducing asymptomatic compartments (A) to the model does not change the dynamics
of symptomatic infections, which are represented by our empirical morbidity data. With the
assumptions described above, both susceptible and infected but asymptomatic individuals are
at risk of symptomatic infection; therefore, the incidence of clinical malaria and the frequency
distribution of clinical cases per person remain the same for both models. We thus apply the
same parameters estimated in the first model (parameter estimation process is fully described
in S1 File), but can now distinguish uninfected and susceptible individuals from those who are
infected but remain asymptomatic, according to the recovery rate γ0.
Asymptomatic parasite carriers, duration of infection and the infectious
reservoir
We simulated several scenarios to address the relative contribution of asymptomatic parasite
carriers to the overall burden of infection and onwards transmission in the community. First,
we assume individuals with asymptomatic infections to be 2, 10 and 30 times less infectious to
mosquitoes than individuals with symptomatic infections (relative infectiousness [RI] of 1/2,
1/10 and 1/30, respectively). Empirical RI estimates vary widely according to the average game-
tocyte density [43] and are close to 1/2 for microscopy-detected asymptomatic P. vivax infec-
tions in Ethiopia [44] but range from 1/14 to 1/29 for asymptomatic infections in Colombia
and Brazil that can be detected only by molecular methods [45, 46].
Next, we assume that, on average, symptomatic infections can be detected by laboratory
methods during 4, 8 and 12 days. Symptomatic infections are curtailed by treatment and their
Fig 8. Susceptible-infected-susceptible (SIS) compartmental model representing the dynamics of malaria in a
heterogeneous host population considering asymptomatic infections. The compartments correspond to the
following epidemiological classes: Si,j represents susceptible individuals from risk group j (1 = low-risk [LR]; 2 = high-
risk [HR]) who have experienced i clinical malaria attacks; Ii,j represents individuals with symptomatic infection from
risk group j who are currently experiencing their ith clinical malaria attack; Ai,j represents individuals with
asymptomatic infections from risk group j with i past clinical malaria attacks. Individuals experience malaria episodes
due to an age-dependent force of infection λ(a) modified by a risk factor xj, and a partial immunity weight σ(i).
Individuals from compartments I and A recover and become susceptible again at rates γ and γ0, respectively.
https://doi.org/10.1371/journal.pcbi.1007377.g008
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average length primarily depends on: (a) the duration of the patent but subclinical period that
precedes full-blown disease manifestations, which remains elusive; (b) the mean time from the
appearance of symptoms to the introduction of chloroquine (CQ)-primaquine (PQ) treatment
(2.7 days in our population [47]), and (c) the mean P. vivax clearance time following CQ-PQ
treatment (1.9 day in our population; [47]). We thus divided the proportion of individuals
within the infected (I) compartments by 7 (= 28/4), 3.5 (28/8) or 2.3 (28/12) to represent the
prevalence of symptomatic blood-stage infections that can be detected by laboratory methods
during the subject’s 28-day stay in the I compartments.
We further assume that asymptomatic blood-stage infections undetected by routine surveil-
lance and left untreated can last between 30 and 180 days. Empirical evidence is rather limited
in this area and the duration is clearly context-specific. Once detected by microscopy, asymp-
tomatic P. vivax infections in 4 years-old Papua New Guinean children lasted on average 15
days [48], but the time elapsed before blood-stage parasite detection has not been measured. If
asymptomatic P. vivax infections were first sampled at a random time point during their tra-
jectory, the time to parasite clearance after detection (15 days) is expected to equal, on average,
the time elapsed before parasite detection, giving a total duration of 30 days. Here we simulate
scenarios with asymptomatic P. vivax infections between 30 and 180 days, which corresponds
to the median duration of asymptomatic P. vivax infections in a cohort study in Vietnam [49].
Finally, we consider the duration of infectiousness to equal the total duration of blood-stage
infection in both symptomatic and asymptomatic carriers, under the assumption that virtually
all blood-stage P. vivax infections comprise mature gametocytes [22,50]. Empirical data from
Brazil show that vivax malaria patients become little infectious within 10 hours of CQ-PQ
treatment [51], but untreated asymptomatic carriers of subpatent P. vivax parasitemia may
remain infectious for up to 2 months after parasite detection [52].
Supporting information
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